EP1941901A4 - Formulation à application externe et ses procédés de préparation et utilisations - Google Patents

Formulation à application externe et ses procédés de préparation et utilisations

Info

Publication number
EP1941901A4
EP1941901A4 EP06753010A EP06753010A EP1941901A4 EP 1941901 A4 EP1941901 A4 EP 1941901A4 EP 06753010 A EP06753010 A EP 06753010A EP 06753010 A EP06753010 A EP 06753010A EP 1941901 A4 EP1941901 A4 EP 1941901A4
Authority
EP
European Patent Office
Prior art keywords
exterior
preparation methods
applied formulation
formulation
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06753010A
Other languages
German (de)
English (en)
Other versions
EP1941901A1 (fr
EP1941901B1 (fr
Inventor
Lei Jin
Jin Pei
Gang Meng
Junmei Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GeneScience Pharmaceuticals Co Ltd
Original Assignee
GeneScience Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GeneScience Pharmaceuticals Co Ltd filed Critical GeneScience Pharmaceuticals Co Ltd
Publication of EP1941901A1 publication Critical patent/EP1941901A1/fr
Publication of EP1941901A4 publication Critical patent/EP1941901A4/fr
Application granted granted Critical
Publication of EP1941901B1 publication Critical patent/EP1941901B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP06753010A 2005-09-27 2006-06-23 Formulation à application externe et ses procédés de préparation et utilisations Not-in-force EP1941901B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2005101057351A CN1939534B (zh) 2005-09-27 2005-09-27 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
PCT/CN2006/001430 WO2007036107A1 (fr) 2005-09-27 2006-06-23 Formulation à application externe et ses procédés de préparation et utilisations

Publications (3)

Publication Number Publication Date
EP1941901A1 EP1941901A1 (fr) 2008-07-09
EP1941901A4 true EP1941901A4 (fr) 2009-08-05
EP1941901B1 EP1941901B1 (fr) 2013-04-03

Family

ID=37899360

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06753010A Not-in-force EP1941901B1 (fr) 2005-09-27 2006-06-23 Formulation à application externe et ses procédés de préparation et utilisations

Country Status (4)

Country Link
US (1) US7858582B2 (fr)
EP (1) EP1941901B1 (fr)
CN (1) CN1939534B (fr)
WO (1) WO2007036107A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010031007A2 (fr) 2008-09-12 2010-03-18 Genvault Corporation Matrices et support pour le stockage et la stabilisation de biomolécules
MX338357B (es) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Compuestos estables de la hormona de crecimiento.
RS59459B1 (sr) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
BR112013018739A2 (pt) * 2010-12-29 2019-09-24 Jade Therapeutics Inc sistema de distribuição de medicamento ocular
AU2012274367A1 (en) * 2011-06-23 2014-01-23 Santen Pharmaceutical Co., Ltd. Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol
US20140107025A1 (en) * 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
US10350232B1 (en) 2013-11-04 2019-07-16 Peter D. Jaillet Medicinal drops
US20150216788A1 (en) * 2014-02-03 2015-08-06 George D. Petito Composition for extracting inks from skin
HRP20200372T1 (hr) * 2014-03-25 2020-06-12 F. Hoffmann - La Roche Ag Postupci proizvodnje poloksamera za upotrebu u mediju za staničnu kulturu
US20170157000A1 (en) * 2014-06-24 2017-06-08 Dermopartners, S.L. Cosmetic product with liposomal growth factors
WO2016172712A2 (fr) 2015-04-23 2016-10-27 Sydnexis, Inc. Composition ophtalmique
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
JP7324566B2 (ja) * 2015-05-28 2023-08-10 ロート製薬株式会社 水性眼科組成物
EP3302426A4 (fr) 2015-05-29 2018-12-05 Sydnexis, Inc. Formulations pharmaceutiques stabilisées de d2o
CN107496442A (zh) * 2017-08-25 2017-12-22 南京斯泰尔医药科技有限公司 一种二氧化氯温度敏感型喷雾凝胶及其制备方法
CN108404121B (zh) * 2018-05-28 2019-02-05 中山未名海济生物医药有限公司 一种重组人生长激素注射液及其制备方法
CN111110831B (zh) * 2020-02-20 2023-08-08 柳州市工人医院 一种溃疡糊剂及其制备方法
KR102874958B1 (ko) * 2020-03-17 2025-10-21 드럭리큐어 에이피에스 흡입용 gm-csf의 액상 제제
CN113244380B (zh) * 2021-06-29 2021-10-08 中美福源生物技术(北京)股份有限公司 一种温度敏感型凝胶损伤修复制剂及其应用
CN115970045B (zh) * 2021-12-10 2024-11-12 广东省人民医院 经皮给药敷料粉剂、经皮给药敷料凝胶及使用方法
CN118126417B (zh) * 2024-05-07 2024-08-02 北京迈迪斯医疗技术有限公司 仿组织穿刺体模材料及其制备方法和仿组织穿刺体模

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018821A1 (fr) * 1998-10-01 2000-04-06 Macromed, Inc. Copolymeres trisequences de polyester polyethyleneglycol, de faible poids moleculaire, biodegradables et dotes de caracteristiques inverses de gelification thermique
US20030203001A1 (en) * 2002-04-25 2003-10-30 Schultz Clyde L. Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
WO2004002534A1 (fr) * 2002-06-27 2004-01-08 Novo Nordisk A/S Utilisation de dimethyle sulfone en tant qu'agent isotonique

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006509A (en) * 1988-06-24 1991-04-09 Harald Waago Use of human growth hormone in treating topical ulcers
JPH07316066A (ja) * 1994-05-26 1995-12-05 Mochida Pharmaceut Co Ltd 創傷治癒剤
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
IT1299191B1 (it) * 1998-06-23 2000-02-29 Sigma Tau Healthscience Spa Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa
CN1127955C (zh) * 2000-07-07 2003-11-19 中山医科大学中山眼科中心 一种眼前段及眼表免疫相关性疾病治疗药物
EP1542768A1 (fr) * 2002-09-20 2005-06-22 Alcon, Inc. Utilisation d'inhibiteurs de la synthese des cytokines dans le traitement des troubles associes a la keratoconjonctivite seche
CN1242812C (zh) * 2003-01-21 2006-02-22 长春金赛药业有限责任公司 重组人粒细胞巨噬细胞集落刺激因子（rhGM－CSF）凝胶剂及其生产方法
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018821A1 (fr) * 1998-10-01 2000-04-06 Macromed, Inc. Copolymeres trisequences de polyester polyethyleneglycol, de faible poids moleculaire, biodegradables et dotes de caracteristiques inverses de gelification thermique
US20030203001A1 (en) * 2002-04-25 2003-10-30 Schultz Clyde L. Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
WO2004002534A1 (fr) * 2002-06-27 2004-01-08 Novo Nordisk A/S Utilisation de dimethyle sulfone en tant qu'agent isotonique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAN C ET AL: "[Treatment of the ocular burn with hormone]", ZHONGHUA SHAO SHANG ZA ZHI = ZHONGHUA SHAOSHANG ZAZHI = CHINESE JOURNAL OF BURNS DEC 2001, vol. 17, no. 6, December 2001 (2001-12-01), pages 330 - 332, XP009118779, ISSN: 1009-2587 *
See also references of WO2007036107A1 *

Also Published As

Publication number Publication date
EP1941901A1 (fr) 2008-07-09
CN1939534B (zh) 2010-12-01
CN1939534A (zh) 2007-04-04
EP1941901B1 (fr) 2013-04-03
US7858582B2 (en) 2010-12-28
WO2007036107A1 (fr) 2007-04-05
US20090156482A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
EP1941901A4 (fr) Formulation à application externe et ses procédés de préparation et utilisations
IL189856A0 (en) New formulation
EP1841854A4 (fr) Dispositifs et procedes de preparation d'echantillons
IL183762A0 (en) Direct compression formulation and process
GB0422525D0 (en) Dermatological compositions and methods
PL1917072T3 (pl) Formulacja witaminowa
IL191072A0 (en) Therapeutic compositions and methods
AU2006339063A8 (en) Macro-diacrylates and macro-polyacrylates
ZA200804299B (en) 3-amino-2-arylpropyl azaindoles and uses thereof
TWI370809B (en) Polyacene and semiconductor formulation
TWI370115B (en) New formulation
EP1968526A4 (fr) Compositions dentaires moussantes et procedes
GB0423565D0 (en) Formulation
GB0412530D0 (en) Formulation
GB0526419D0 (en) Formulation
GB0517673D0 (en) Formulation
ZA200802953B (en) Solid vaccine formulation
IL186337A0 (en) Stannsoporfin compositions and administration
PL2215908T3 (pl) 2-alkilo-cykloalk(en)ylo-karboksamidy i ich zastosowanie jako fungicydów
ZA200805079B (en) Immunostimulatory compositions and methods
IL186277A0 (en) Dnt-maleate and methods of preparation thereof
GB0501030D0 (en) Formulation
GB0504940D0 (en) Vaccine formulation
GB0501348D0 (en) Compositions and methods
PL1928232T3 (pl) Stała formulacja

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080312

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB

DAX Request for extension of the european patent (deleted)
RBV Designated contracting states (corrected)

Designated state(s): DE FR GB

A4 Supplementary search report drawn up and despatched

Effective date: 20090706

17Q First examination report despatched

Effective date: 20091021

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE FR GB

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006035439

Country of ref document: DE

Effective date: 20130529

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20140106

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602006035439

Country of ref document: DE

Effective date: 20140101

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20140228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130701

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20160617

Year of fee payment: 11

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20170623

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170623